Reuters logo
BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib
2017年4月25日 / 晚上8点17分 / 5 个月前

BRIEF-Galapagos announces new phase 2 proof-of-concept study with filgotinib

April 25 (Reuters) - Galapagos Nv:

* Galapagos announces new phase 2 proof-of-concept study with filgotinib in cutaneous lupus erythematosus

* Says study is being led by filgotinib collaboration partner Gilead Sciences Inc Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below